ReviewImmunological reviews2015
Human IgG4: a structural perspective.
Review in Immunological reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02654288 (Dynamic Changes of the Serum Level of Immunoglobulin G4), which is not on this map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dynamic Changes of the Serum Level of Immunoglobulin G4(IgG4) and Interleukin-10(IL-10) in the Patients of Pancreatic Cancer After Gemcitabine-based Chemotherapy
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 166 citations in OpenAlex.
- Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.Blood · 2025Trial
- Serum PLA2R-IgG4/PLA2R-IgG ratio dynamics reveal pathogenic autoantibody subclass switch during progression of PLA2R-associated membranous nephropathy.Annals of medicine · 2026Article
- Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.Blood · 2026Article
- Higher serum IgG4 levels correlate with better quality of life in mild Graves' orbitopathy: a preliminary report.Endocrine connections · 2026Article
- Article
- Targeting Sialidase to PD1 Enhances T cell Function and Tumor Control.ACS central science · 2025Article
- Clinical characterization of malignant lymphoma mimicking IgG4-related disease.Clinical rheumatology · 2025Article
- Tumors in the setting of dupilumab use: A review of the literature.The World Allergy Organization journal · 2025Review
- Tracing the evolutionary pathway of IgG4: Implications for immune tolerance and regulation.Allergy · 2025Article
- Retroperitoneal fibrosis in presence of autoimmune coagulation factor XIII deficiency result in recurrent critical post-operative hemorrhage: a case report and molecular research with new insights.Frontiers in immunology · 2025Article
- Some Human Anti-Glycan Antibodies Lack the Ability to Activate the Complement System.Antibodies (Basel, Switzerland) · 2024Article
- Implications of Serum IgG4 Levels for Pancreatobiliary Disorders and Cancer.Journal of clinical medicine · 2024Article
- A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2024Article
- Streamlined Multi-Attribute Assessment of an Array of Clinical-Stage Antibodies: Relationship Between Degradation and Stability.Applied spectroscopy · 2024Article
- Using atomistic solution scattering modelling to elucidate the role of the Fc glycans in human IgG4.PloS one · 2024Article
- The fate of immune complexes in membranous nephropathy.Frontiers in immunology · 2024Review
- Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation.Biochimica et biophysica acta. General subjects · 2023Review
- Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.Cancer communications (London, England) · 2023Review
- Roles of IgG4 and IgG4/IgG ratio to IgG4-related disease in patients with elevated serum IgG4 level.Clinical rheumatology · 2023Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
IgG4, the least represented human IgG subclass in serum, is an intriguing antibody with unique biological properties, such as the ability to undergo Fab-arm exchange and limit immune complex formation. The lack of effector functions, such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, is desirable for therapeutic purposes. IgG4 plays a protective role in allergy by acting as a blocking antibody, and inhibiting mast cell degranulation, but a deleterious role in malignant melanoma, by impeding IgG1-mediated anti-tumor immunity. These findings highlight the importance of understanding the interaction between IgG4 and Fcγ receptors. Despite a wealth of structural information for the IgG1 subclass, including complexes with Fcγ receptors, and structures for intact antibodies, high-resolution crystal structures were not reported for IgG4-Fc until recently. Here, we highlight some of the biological properties of human IgG4, and review the recent crystal structures of IgG4-Fc. We discuss the unexpected conformations adopted by functionally important Cγ2 domain loops, and speculate about potential implications for the interaction between IgG4 and FcγRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.